18 June 2013
Keywords: Novartis, Alisporivir, Hepatitis C, Debiopharm
Article | 14 November 2011
The clear conclusion from a clinical trial of alisporivir (DEB025, from Swiss drug major Novartis [NOVN: VX]), an oral host-targeting ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 November 2011
15 November 2011
17 June 2013
© 2013 thepharmaletter.com